JPS5914032B2 - Bistrimethoxybenzylpiperazinoalkanes - Google Patents

Bistrimethoxybenzylpiperazinoalkanes

Info

Publication number
JPS5914032B2
JPS5914032B2 JP51040784A JP4078476A JPS5914032B2 JP S5914032 B2 JPS5914032 B2 JP S5914032B2 JP 51040784 A JP51040784 A JP 51040784A JP 4078476 A JP4078476 A JP 4078476A JP S5914032 B2 JPS5914032 B2 JP S5914032B2
Authority
JP
Japan
Prior art keywords
substance
hydrochloride
recrystallized
yield
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP51040784A
Other languages
Japanese (ja)
Other versions
JPS52131590A (en
Inventor
博 村井
良明 青柳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Shinyaku Co Ltd
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Priority to JP51040784A priority Critical patent/JPS5914032B2/en
Priority to US05/783,561 priority patent/US4100285A/en
Priority to DE19772714996 priority patent/DE2714996A1/en
Priority to GB14537/77A priority patent/GB1565431A/en
Priority to CH446377A priority patent/CH629197A5/en
Priority to CH446277A priority patent/CH629196A5/en
Priority to FR7710859A priority patent/FR2347359A1/en
Publication of JPS52131590A publication Critical patent/JPS52131590A/en
Publication of JPS5914032B2 publication Critical patent/JPS5914032B2/en
Expired legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

【発明の詳細な説明】 本発明は次の一般式 CH3OOCH3 12)n−〇CH2さ0CH3(I) *血性心疾患治療剤として有用である。[Detailed description of the invention] The present invention is based on the following general formula CH3OOCH3 12) n-○CH2sa0CH3(I) *Useful as a therapeutic agent for blood-related heart disease.

これら薬理作用の一例として、モルモツト摘出心臓にお
けるLangendorff法による心臓脈管に対する
活性およびマウスに対するLD5o値を第1表ゞ0 に
示す。
As an example of these pharmacological actions, Table 1 shows the activity on cardiovascular vessels according to the Langendorff method in isolated hearts of guinea pigs and the LD5o value for mice.

表 これらの化合物はいずれも種々の方法によつて合成する
ことが最も一般的には次の化学構造式(l)で表わされ
るトリメタジジン2モルにジハロゲノアルカン1モルを
作用せしめる事により容易に合成する事ができる。
Table All of these compounds can be synthesized by various methods, but most commonly, they can be easily synthesized by reacting 1 mole of dihalogenoalkane with 2 moles of trimetazidine, which is represented by the following chemical structure (l). I can do that.

又ジピペラジノアルカンをベンジル化する方法やN−ベ
ンジルジエタノールアミンの活性化誘導体2モルとジア
ミノアルカン1モルとによりピペラジン環閉環を行なう
方法等も有利に使用し得る。以下実施例により更に具体
的に説明する。
Also advantageously used are a method of benzylating a dipiperazinoalkane and a method of performing piperazine ring closure using 2 moles of an activated derivative of N-benzyldiethanolamine and 1 mole of a diaminoalkane. This will be explained in more detail below with reference to Examples.

実施例 1 (n=2) ()物質塩酸塩10.07、無水炭酸カリウム137お
よびジブロムエタン5.6yをDMFlOOml中50
〜60℃で3時間加温攪拌、以下常法により処理して得
られる塩基性物質をアセトンより再結晶する。
Example 1 (n=2) (10.07% of the substance hydrochloride, 137% of anhydrous potassium carbonate and 5.6y of dibromoethane in 50ml of DMFlOOml)
The basic substance obtained by heating and stirring at ~60° C. for 3 hours and subsequent treatment using a conventional method is recrystallized from acetone.

融点121〜122℃、収量3.9t0 実施例 2 (n=4) (l)物質塩酸塩5.07、無水炭酸カリウム9.07
、ジクロルブタン1.0VをDMSOlOOd中60〜
70℃で10時間加温攪拌、以下常法により処理し、塩
基性物質をクロロホルム抽出。
Melting point 121-122°C, yield 3.9t0 Example 2 (n=4) (l) Substance hydrochloride 5.07, anhydrous potassium carbonate 9.07
, dichlorobutane 1.0V in DMSOlOOd 60~
The mixture was heated and stirred at 70°C for 10 hours, followed by treatment using a conventional method, and basic substances were extracted with chloroform.

クロロホルム抽出液を稀塩酸と振盪し、塩酸層をアルカ
リ性として目的物質をエーテル抽出する。マレイン酸4
モルを加えてマレイン酸塩としてイソプロパノールより
再結晶する。融点95〜98℃、収量1.507。
The chloroform extract is shaken with dilute hydrochloric acid, the hydrochloric acid layer is made alkaline, and the target substance is extracted with ether. maleic acid 4
The maleate salt is recrystallized from isopropanol. Melting point 95-98°C, yield 1.507.

実施例 3 (n−6) (l)物質塩酸塩6.77、ジクロロヘキサン1.87
および無水炭酸カリウム7.07をDMF7Oml中5
0〜60℃で16時間加温撹拌、常法により処理し、塩
基性物質をクロロホルムで抽出後1%酢酸水で逆抽出し
、酢酸層より目的物質を得る。
Example 3 (n-6) (l) Substance hydrochloride 6.77, dichlorohexane 1.87
and anhydrous potassium carbonate 7.07 in DMF 70ml
The mixture is heated and stirred at 0 to 60°C for 16 hours, treated in a conventional manner, and the basic substance is extracted with chloroform, followed by back extraction with 1% aqueous acetic acid, and the target substance is obtained from the acetic acid layer.

塩酸塩とし含水ジオキサンより再結晶する。It is converted into hydrochloride and recrystallized from aqueous dioxane.

融点23『C(分解)、収量0.9570実施例 4 (n−8) ()物質塩酸塩9.0y1ジクロロオクタン3.0f7
および無水炭酸カリウム161をDMF7Oml中65
〜70℃で12時間加温攪拌、以下実施例3と同様に処
理し、塩酸塩とし含水イソプロパノールより再結晶する
Melting point 23'C (decomposition), yield 0.9570 Example 4 (n-8) () Substance hydrochloride 9.0y1 dichlorooctane 3.0f7
and anhydrous potassium carbonate 161 in DMF 70ml
The mixture was heated and stirred at ~70°C for 12 hours, then treated in the same manner as in Example 3, and recrystallized from aqueous isopropanol to form a hydrochloride.

融点230℃以上(分解)、収量2.27。Melting point: 230°C or higher (decomposition), yield: 2.27.

Claims (1)

【特許請求の範囲】 1 次の一般式( I )すなわち ▲数式、化学式、表等があります▼( I )(式中、n
は2〜8の整数を示す。 )で表わされるビストリメトキシベンジルピペラジノア
ルカン類。
[Claims] 1. The following general formula (I), that is, ▲ there are mathematical formulas, chemical formulas, tables, etc. ▼ (I) (in the formula, n
represents an integer from 2 to 8. ) bistrimethoxybenzylpiperazino alkanes represented by
JP51040784A 1976-04-09 1976-04-09 Bistrimethoxybenzylpiperazinoalkanes Expired JPS5914032B2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP51040784A JPS5914032B2 (en) 1976-04-09 1976-04-09 Bistrimethoxybenzylpiperazinoalkanes
US05/783,561 US4100285A (en) 1976-04-09 1977-04-01 N-substituted trialkoxybenzyl piperazine derivatives
DE19772714996 DE2714996A1 (en) 1976-04-09 1977-04-04 N-SUBSTITUTED TRIALCOXYBENZYLPIPERAZINE DERIVATIVES
GB14537/77A GB1565431A (en) 1976-04-09 1977-04-06 N-substituted trialkoxybenzylpiperazine derivatives
CH446377A CH629197A5 (en) 1976-04-09 1977-04-07 Process for the preparation of N-substituted trialkoxybenzylpiperazine derivatives
CH446277A CH629196A5 (en) 1976-04-09 1977-04-07 Process for the preparation of N-substituted trialkoxybenzylpiperazine derivatives
FR7710859A FR2347359A1 (en) 1976-04-09 1977-04-08 N-SUBSTITUTED TRIALCOXYBENZYLPIPERAZINE DERIVATIVES AND THEIR PHARMACEUTICAL USES, ESPECIALLY FOR THEIR VASODILATOR ACTION

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP51040784A JPS5914032B2 (en) 1976-04-09 1976-04-09 Bistrimethoxybenzylpiperazinoalkanes

Publications (2)

Publication Number Publication Date
JPS52131590A JPS52131590A (en) 1977-11-04
JPS5914032B2 true JPS5914032B2 (en) 1984-04-02

Family

ID=12590238

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51040784A Expired JPS5914032B2 (en) 1976-04-09 1976-04-09 Bistrimethoxybenzylpiperazinoalkanes

Country Status (1)

Country Link
JP (1) JPS5914032B2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR81827B (en) * 1983-03-21 1984-12-12 Boehringer Ingelheim Ltd

Also Published As

Publication number Publication date
JPS52131590A (en) 1977-11-04

Similar Documents

Publication Publication Date Title
DK149886B (en) METHOD OF ANALOGY FOR PREPARATION OF 5-METHYLISOXAZOLE-4-CARBOXYLIC ACID (4-TRIFLUOROMETHYL) -ANILIDE
DK157932B (en) 1,3-DIHYDRO-6-METHYL-FURO- (3,4-C) -PYRIDINE DERIVATIVES AND PHARMACEUTICAL ACCEPTABLE SALTS THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE
IL49205A (en) 5-chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole its production and pharmaceutical compositions containing it
NO155814B (en) PROCEDURE FOR THE PREPARATION OF ANTIBIOTIC A / 16686 FACTORS A1, A2, A3.
JPS6253966A (en) Novel pyridine derivative
US3475408A (en) N(6) alkenyl 5-substituted adenosine
JPS5914032B2 (en) Bistrimethoxybenzylpiperazinoalkanes
US2704757A (en) 5-hydroxy-3, 4, 5, 6-tetrahydropyriminines
SU965354A3 (en) Process for producing tetrahydroquinoline derivatives
JPS633861B2 (en)
JPS5842195B2 (en) Method for producing thiazoloisoquinoline derivatives
CA1110229A (en) 3-amino-17a-aza-d-homoandrostane derivatives, their preparation and pharmaceutical compositions containing them
JPH0751572B2 (en) Heterocyclic disulfite
JPS607991B2 (en) Production method of piperazine derivatives
JPS61158980A (en) 8 alpha-acylaminoergolines, manufacture and medicinal composition
JPS60132937A (en) N-(methoxyphenacyl)amine derivative, therapeutic compositionand manufacture
KR790001667B1 (en) Process for the preparation of bis-trimethoxy benzyl piperazyno alkanes
JPS62108863A (en) 2-pyridylacetic derivative, its preparation and medicine containing the same
US3466290A (en) 9,10-dihydro-4h-benzo(4,5)cyclohepta(1,2-b)thiophene ethers
JPS5944314B2 (en) Manufacturing method of indazole derivatives
US3041345A (en) Process of preparation of isonicotinyl hydrazones and hydrazides
JPS61233678A (en) Benzylpiperazine derivative
CA1050541A (en) Process for the preparation of benzylamines
US2469554A (en) The process of preparing the lactone of 2 methyl 3 hydroxy 4 carboxy 5 hydroxymethyl pyridine
US3948899A (en) α-Cyanobenzylpiperazines and a process for producing the same